2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 223

The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry
Abstract Number: 224

Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab
Abstract Number: 225

U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014
Abstract Number: 226

Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
Abstract Number: 227

Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections
Abstract Number: 228

Widespread Chronic Use of Proton-Pump Inhibitors and Potential for Drug-Drug Interactions in Rheumatoid Arthritis and Lupus Patients
Abstract Number: 229

Disability Status, Mortality, and Leading Causes of Death in Seropositive Rheumatoid Arthritis Patients: A Population-Based Study in Korea
Abstract Number: 230

Increased Prevalence of Coronary Artery Disease in Patients with Chest Pain and Seropositive Rheumatoid Arthritis: An Analysis from a Clinical Computed Tomography-Based Large-Scale Population Cohort
Abstract Number: 231

Rates of Influenza Vaccination in a Cohort of Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Abstract Number: 232

Inpatient Mortality in Transition-Aged Youth with Rheumatic Disease: An Analysis of the National Inpatient Sample
Abstract Number: 233

TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population
Abstract Number: 234

Population-Based Estimates of Fatigue Prevalence Among Adults Aged >18 Years with and without Arthritis, United States, 2015-2016
Abstract Number: 235

Clinical Predictors and Risk of Methotrexate Induced Liver Fibrosis
Abstract Number: 236

Hypogammaglobulinemia and Infection Risk in Patients Treated with Rituximab
Abstract Number: 237

The Risk of Serious and Opportunistic Infections in Rheumatologic Patients on Interleukin Inhibitors: A Systematic Review and Meta-Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].